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Abstract 
Background 
High cholesterol may be a modifiable risk factor for prostate cancer but results have been 
inconsistent and subject to potential “reverse causality” where undetected disease modifies 
cholesterol prior to diagnosis. 
Methods 
We conducted a prospective cohort study of 12,926 men who were enrolled in the Midspan 
studies between 1970 and 1976 and followed up to 31st December 2007. We used Cox-
Proportional Hazards Models to evaluate the association between baseline plasma cholesterol 
and Gleason grade-specific prostate cancer incidence. We excluded cancers detected within at 
least 5 years of cholesterol assay. 
Results 
650 men developed prostate cancer in up to 37 years’ follow-up. Baseline plasma cholesterol 
was positively associated with hazard of high grade (Gleason score≥8) prostate cancer 
incidence (n=119). The association was greatest among men in the 2nd highest quintile for 
cholesterol, 6.1 to <6.69 mmol/l, Hazard Ratio 2.28, 95% CI 1.27 to 4.10, compared with the 
baseline of <5.05 mmol/l. This association remained significant after adjustment for body 
mass index, smoking and socioeconomic status. 
Conclusions 
Men with higher cholesterol are at greater risk of developing high-grade prostate cancer but 
not overall risk of prostate cancer. Interventions to minimise metabolic risk factors may have 
a role in reducing incidence of aggressive prostate cancer. 
Keywords 
Cholesterol, Prostate cancer, Incidence, Gleason grade 
Background 
The incidence of prostate cancer has increased over several decades such that it is now the 
most commonly diagnosed cancer among men in Europe and the USA [1,2]. There is 
evidence that increasing age, genetic predisposition [3,4] and ethnicity [5] are risk factors for 
prostate cancer while opportunistic testing may partly explain temporal increases and 
international variations in incidence [1]. Prostate cancer is about six times more common in 
more developed compared to less developed countries, suggesting that modifiable Western 
lifestyle factors may have a causal role [6]. It has been observed for about a century that the 
levels of cholesterol, fatty deposits, lecithin and some other lipids in the diseased prostate are 
elevated [7]. Several studies have explored the relationship between serum cholesterol levels 
and the incidence of prostate cancer and its associated mortality with inconsistent conclusions 
[8-13]. Some found a positive association between cholesterol and prostate cancer mortality 
[8,14] while others revealed either an inverse relationship [10,13] or no overall association 
with incidence [9,11]. 
Three recent reports have suggested that while serum cholesterol has no association with 
overall incidence of prostate cancer, patients with low cholesterol are less likely to have high 
grade (Gleason score ≥8) disease [15-17]. In two of these studies, follow-up was short (3.1 
and 5.5 years) [16,17] and none excluded early events so that “reverse causality”—that is, 
cholesterol was modified by undiagnosed disease and not a causal factor for it—may have 
partly explained their observations. 
Given that age, genetics and ethnicity are not modifiable risk factors, the potential role of 
cholesterol on prostate cancer risk may be of clinical importance. In the present study we 
evaluated the association between plasma cholesterol level and both overall and grade-
specific prostate cancer incidence, using two of the Midspan prospective cohort studies with 
up to 37 years’ follow-up. Individuals diagnosed with prostate cancer within 5 years of 
baseline cholesterol assay were excluded to reduce the potential effects of “reverse 
causality.” 
Methods 
Cohort characteristics 
The Midspan studies began in the 1960s and 1970s in Scotland, UK. Their methods have 
been described in detail elsewhere [18]. We included two Midspan studies in this research 
paper. The first, the Collaborative study, was conducted on employed men and women aged 
from 21 to 75 years from 27 workplaces in Glasgow, Clydebank and Grangemouth between 
1970 and 1973 [19]. The second Midspan study, the Renfrew/Paisley study, was a general 
population study of residents of the towns of Renfrew and Paisley, conducted between 1972 
and 1976. All residents aged 45–64 years were invited to take part and 80% accepted [20]. 
Because of the geographical proximity of the study populations, a small number of 
individuals participated in both cohorts. For individuals with more than one record, only the 
earliest record was used. Study protocols consisted of a self-administered questionnaire 
followed by a screening examination at a specially set-up clinic. Questions included 
demographic details, occupation, lifestyle habits, including smoking, and health [20]. As part 
of the screening examination, measurements were made for height and weight and blood 
pressure. A blood sample was obtained at baseline screening for the measurement of total 
circulating plasma cholesterol. Body mass index (BMI) was calculated from weight (in kg) 
divided by height (in metres) squared and categorised according to the World Health 
Organisation [21] classification in which BMI < 18.50 is underweight, 18.50 to 24.99 is the 
normal range, 25.00 to 29.99 is overweight and ≥30.00 is obese. A blood sample was 
obtained at baseline screening for the measurement of total circulating plasma cholesterol 
[20].Socioeconomic status was derived from occupation according to the relevant version of 
the General Register Office Classification of Occupation [22] and graded into six categories: 
I [23], II (intermediate), III (skilled non-manual), III (skilled manual), IV (partly skilled) and 
V (unskilled) [20]. Ex-smokers were defined as reporting giving up smoking at least a year 
before screening, otherwise they were defined as current smokers. Cholesterol was 
categorised by quintiles. Only records for male participants were used for this study. 
Follow up 
Follow up for mortality was carried out by flagging Midspan participants with the National 
Health Service Central Register. Deaths were then notified to the Midspan team on a monthly 
basis. Information on cancer registrations and hospital activity was obtained by linkage to the 
Scottish Morbidity Records (SMR) data and was complete from 1972 onwards [24]. Follow 
up began on the date of screening to the date of cancer incidence, date of death, date of 
embarkation (leaving the United Kingdom) or the censor date of 31st December 2007, 
whichever came first. 
Ethical approval 
The Privacy Advisory Committee of the Information Services Division of NHS Scotland 
gave permission for the linked data to be used in this study. 
Risk factor and outcome definitions 
Prostate cancer was defined as International Classification of Diseases (ICD) revision 9 codes 
185 and ICD-10 codes C61. Prostate cancer incidence was determined if it was included in 
any cancer registration (SMR06), any diagnosis position of an acute hospital record (SMR01) 
or any position on the death record. Where a patient had prostate cancer recorded on more 
than one type of record, the earliest date was taken as time of first diagnosis. The Gleason 
grading system is a method used to describe the morphology of clinical PC. Data on Gleason 
score were available from the cancer registry (SMR06). The Scottish Cancer Registry began 
recording Gleason score from 1st January 1997 and therefore the analysis of grade-specific 
associations between cholesterol and PC was restricted to the follow up of the surviving 
cohort as of 1st of January 1997 and these were just records from SMR06. 
Statistical analysis 
Cox proportional hazards models were used to estimate hazard ratios (HRs) for PC incidence 
from screening and for specific histological grade from 1st January 1997. For grade specific 
analysis, we excluded men who had died or been diagnosed with PC before 1st January 1997. 
Separate models were run for each Gleason category, and men with PC and other Gleason 
scores were censored at their date of diagnosis. Age was taken as the timescale with 
censoring occurring on 31 December 2007. The alternative approach of using time since 
screening as the timescale was also investigated [25]. The estimates presented in this study 
are obtained by using age as the time scale. All analyses were conducted using STATA 
version 11 (StataCorp, College Station, TX, USA). The following covariates were included in 
the multivariate model: smoking status, BMI and socioeconomic status and results are 
presented based on this model. There is some evidence that increasing height significantly 
increases the risk of developing PC, so BMI was replaced with height in the second model 
and estimates for height are presented when BMI was not included in the model. There were 
missing data for some covariates: 89 in socioeconomic status; 1 in height and weight; 1 in 
smoking status; Total missing data for all covariates was less than 0.01% which did not 
change any of the associations when we ran the analysis both including those observations 
after imputations and excluding these individuals. We presented the final results after 
imputations in which missing information on continuous variables was replaced by the 
sample mean while for categorical variables missing data were replaced by modal values. The 
lowest category was used as referent for the cholesterol and all other categorical covariates. 
The analysis was repeated by combining the two highest quintiles of cholesterol. 
Furthermore, analysis was also carried out by using the recommended clinical cut offs for 
adults cholesterol level, where cholesterol level of less than 5.1 mmol/L was considered as 
desirable, 5.1 to <6.21 mmol/L as borderline high and ≥6.21 mmol/L as high [26]. Analysis 
was also stratified based on BMI categories (i.e. desirable, overweight, obese), and also by 
using the median BMI of the sample, consistent with an earlier study [15]. Adherence to the 
proportional hazards assumption was investigated by plotting smoothed Schoenfeld residuals 
against time; no violations of the assumption were identified. All statistical tests were two 
tailed and statistical significance was taken as p < 0.05. The analysis was carried out after 
excluding individuals diagnosed with PC within 5 years of screening to minimise 
confounding due to the possible effects of early disease affecting cholesterol [27]. 
Results 
Data from 13,071 men were available for analysis, 6022 (46.1%) from the Collaborative 
Study and 7049 (53.9%) from Renfrew/Paisley. Five Collaborative and nine Renfrew/Paisley 
participants were lost to follow up, and 42 Collaborative and 55 Renfrew/Paisley participants 
had missing cholesterol data. Twenty six individuals who participated in both the studies 
were excluded from the Renfrew/Paisley study. Eight individuals diagnosed with PC in the 
first 5 years of screening were also excluded from the analysis. Our final sample therefore 
comprised 12,926 men followed-up for a total of 293,284 person-years. The median follow-
up period was 24 years, maximum 37 years. Median age was 51 years at the time of 
screening (range, 21–75 years). 
Baseline and outcome characteristics for the study are shown in Table 1. Six hundred and 
fifty men with PC were identified. Among 307 cancers that occurred from 1997 onward 
(when Gleason score was included in cancer registry data), 119 (38.8%) were high grade 
(Gleason score≥8), 57 (18.6%) were intermediate grade (Gleason=7), 64 (20.8%) low grade 
(Gleason≤6) and the remaining 67 (21.8%) were of unknown Gleason score. Increasing 
weight and BMI were positively associated with cholesterol while current smoking and lower 
socioeconomic status were inversely associated with cholesterol (data not shown). Mean 
plasma cholesterol level did not differ (p=0.27) between men who were diagnosed with 
prostate cancer (5.85 mmol/l ± 0.99) and those who remained free from it (5.87 mmol/l ± 
0.99). The mean time between screening (plasma cholesterol measurement) and the prostate 
cancer diagnosis was 22.9 (SD 7.84) years. 
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Using age as the time-scale we found no convincing association between cholesterol and 
overall hazard of PC, nor any consistent relationship within low and intermediate grade 
disease (Table 2). However, the hazard increased consistently from the lowest to the second 
highest quintile of cholesterol among high grade disease (Gleason score ≥ 8). We explored 
the relationship between cholesterol and high grade disease further in Table 3. After 
adjustment for BMI, smoking and socioeconomic status, a progressive increase in risk of high 
grade prostate remained between the lowest and second highest quintiles of cholesterol. This 
is more clearly shown in Figure 1, in which the smoothed hazard of the most aggressive PCs 
(Gleason score≥8) increased with increasing cholesterol and then declined. As no significant 
association was observed between the highest quintile of cholesterol and risk of high grade 
disease, we combined the last two quintiles to further investigate the association. We 
observed significantly higher risk (HR 1.88, 95 CI 1.08–3.27, p-value 0.03) of developing 
high grade disease among men in the highest cholesterol category (combination of 4th and 5th 
quintile). Furthermore, we also investigated the association between cholesterol and risk of 
high grade disease using the clinical cut points. Men in the higher cholesterol group (≥ 6.21 
mmols/l) had significantly increased risk of developing high grade disease (1.75, 95% CI 
1.03–2.97, p value 0.036) compared to the desirable cholesterol group (<5.1 mmols/l) after 
adjustment for BMI, smoking and socioeconomic status (data not shown).
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Table 3 Multivariate hazard ratios (HR) for all prostate cancers and those with Gleason grade 
≥ 8 by cholesterol quintiles 
  All Prostate Cancers Prostate cancers Gleason ≥ 8 
  Baseline Sample From 1st January 1997 
  % n Hazard Ratio (95% 
CI) 
% n Hazard Ratio (95% 
CI) 
Cholesterol 
(mmol/L) 
quintiles 
          
< 5.05 5.1 (138)  1 1.2 (17)  1 
5.06 – <5.57 4.7 (121) 0.89 (0.70, 1.14) 1.5 (19) 1.18 (0.62, 2.28) 
5.58 – <6.09 5.1 (145) 0.95 (0.75, 1.21) 2.1 (30) 1.72 (0.95, 3.13) 
6.1 – < 6.69 5.5 (125) 1.01 (0.79, 1.29) 2.8 (33) 2.34 (1.30, 4.23) 
≥6.7 4.8 (121) 0.95 (0.74, 1.22) 1.7 (20) 1.40 (0.73, 2.71) 
BMI (kg m-2)           
<25 (Under 
& Desirable 
weight) 
4.8 (279)  1 2.1 (61)  1 
25 – <30 
(Overweight) 
5.3 (320) 1.02 (0.86, 1.20) 1.5 (47) 0.69 (0.47, 1.02) 
≥30 (Obese) 4.6 (51) 1.03 (0.77, 1.40) 2.3 (11) 1.18 (0.62, 2.27) 
Smoking           
Never 
smoker 
6.6 (149)  1 2.1 (31)  1 
Smoker 3.9 (294) 0.90 (0.73, 1.09) 1.6 (52) 0.92 (0.59, 1.45) 
Ex-smoker 6.6 (207) 1.03 (0.77, 1.40) 2.1 (36) 1.06 (0.65, 1.72) 
Social Class           
I&II 5.8 (190)  1 1.9 (38)  1 
IIIN 5.6 (108) 1.10 (0.87, 1.40) 2.2 (22) 1.21 (0.71, 2.05) 
IIIM 4.7 (217) 1.03 (0.85, 1.26) 1.6 (33) 0.95 (0.59, 1.53) 
IV&V 4.2 (135) 0.91 (0.73, 1.14) 1.9 (26) 1.15 (0.69, 1.92) 
Height (cm)           
≤165.1 4.9 (120)  1 1.8 (17)  1 
165.2-170 4.7 (126) 1.05 (0.82, 1.35) 1.8 (23) 1.27 1(0.68, 2.37) 
170.1-172.72 4.2 (121) 1.11 (0.86, 1.43) 1.4 (22) 1.54 (0.61, 2.19) 
172.73-177.8 7.5 (165) 1.27 (1.01, 1.61) 3.2 (36) 1.69 (0.94, 3.05) 
≥177.9 4.3 (118) 1.35 , (1.04 1.75) 1.3 (21) 1.32 (0.68, 2.55) 
Multivariate hazard ratios and 95% CIs were obtained by using age as time-scale; all 
covariates were included in the model except height. Estimates for height were obtained by 
replacing the BMI with height 
Figure 1 Functional form of the association of cholesterol with the relative hazard of Gleason 
8 to 10 prostate cancers estimated in a Cox proportional hazards model using age as the time 
axis. The function was fitted using restricted cubic splines with three knots (X). The function 
was standardized such that the HR was 1 at the mean cholesterol level of the lowest quintile. 
Dotted lines indicate the 95% confidence intervals 
We further stratified the analysis based on BMI. The association between cholesterol level 
and high grade prostate cancer differed by BMI,however, no clear relationship emerged when 
using the desirable, overweight and obese categories, due to smaller number of aggressive PC 
cases in two highest cholesterol quintiles of obese group (n=7), so analysis was then stratified 
based on the median BMI of the sample. There was no evidence of an association between 
cholesterol level and risk of high grade disease in men with BMIs lower than 25.3. However, 
among men with high BMI (≥ 25.3, median of the sample), those in the second highest 
cholesterol quintile were significantly more likely to develop high grade disease (HR 9.98, 
95% CI 2.33–42.78, p value 0.002) after adjustments for socioeconomic status and smoking 
status (data not shown). Similarly among men with higher BMI, when we combined the two 
highest cholesterol quintiles, those in the highest category had seven times higher risk of 
developing high grade disease compared to the lowest cholesterol group. We also examined 
the interaction between cholesterol and BMI within multivariate model, however, no 
significant interaction was observed between BMI and cholesterol (p for interaction 0.86). 
We also noted a progressive increase in risk of all PCs with increasing height in univariate 
analysis, for this reason we also ran a multivariate model using height instead of BMI to 
examine any confounding effect, however, the associations of cholesterol and height with PC 
incidence remained consistent after adjusting for smoking and socioeconomic status (Table 
3). 
Discussion 
We found that plasma cholesterol was positively associated with increased risk of aggressive 
prostate cancer but not with overall risk of developing the disease in this population-based 
prospective cohort study. Our findings are consistent with others reported on United States 
populations [15-17]. Similarly, data from the Swedish Apolipoprotein Mortality Risk 
(AMORIS) study reported no evidence of a relationship between hypercholesterolemia and 
overall prostate cancer risk [28]. However, a large study of male Finnish smokers, reported a 
positive association between increasing total cholesterol level and overall risk of prostate 
cancer particularly advanced stage prostate cancer [29]. The association further strengthened 
when they restricted the analysis to the cases diagnosed after 10 years from the baseline. 
However, this study did not find any association between aggressive disease, which may be 
because Gleason score was only available for 25% of the prostate cancer patients [29]. 
Several underlying mechanisms by which cholesterol and prostate carcinogenesis may be 
linked have been proposed. Prostate cancer cells tend to over accumulate cholesterol in their 
cell membrane, forming large lipid rafts which in the cancer cells may facilitate pro-
carcinogenic cell signalling [29-31]. Moreover, several other pathways which are considered 
vital in carcinogenesis, such as sonic hedgehog and Akt pathways, are also cholesterol 
sensitive [32,33]. Thus, having a lower cholesterol level may inhibit these pro-carcinogenic 
activities in the prostate cells. 
Generally, an association has been reported between low cholesterol and increased risk of 
many cancer types and their associated mortality [9,11,12] which has been ascribed to reverse 
causality; that is, early undiagnosed cancers lead to behavioural and physiological changes 
that reduce plasma cholesterol. The longer period between baseline cholesterol assay and 
diagnosis in our study (about 21 years for grade-specific analyses) compared to others 
suggests that reverse causality is unlikely to have been responsible for the observed 
association. Moreover, any such effect would have been expected to attenuate rather than 
exaggerate the association. 
The potential clinical implications of our findings are that increasing obesity and associated 
dyslipidemia may have been responsible for the increasing incidence of prostate cancer and 
that modifying cholesterol may reduce incidence of more aggressive disease. The evidence 
that statins may reduce prostate cancer incidence remains equivocal. Two meta-analyses and 
a subsequent cohort study did not find any relationship between statin use and prostate cancer 
[34-36]. However, Platz and Jacobs found associations between statin use and lower risk of 
advanced prostate cancer only and suggested that plausible biological mechanisms may 
existed, for example 3-hydroxy-3-methylglutaryl (HMG) coenzyme A reductase inhibition 
may reduce prostate cancer cell survival by interfering with membrane-associated signalling. 
In the absence of more consistent evidence on the effects of statins on prostate cancer, the 
most effective means of reducing incidence of the disease may therefore be through effective 
weight management. 
Our research is based on one of the largest population based prospective studies in the United 
Kingdom and used cancer incidence data for the grade-specific analyses, rather than death 
records for cancer outcomes. Mortality data are a product of both incidence and case fatality, 
and do not allow risk factors to be individually differentiated. Furthermore, high cholesterol 
may increase the risk of death from other causes in prostate cancer patients and not 
necessarily be a causal factor for prostate cancer itself. Our study has larger numbers of 
incident cancers (n=650), longer follow up and lower losses to follow up (0.1%) compared 
with earlier studies [15,16]. However, our study has some weaknesses. The number of cases 
with aggressive PC was smaller; this may have influenced our results in some analyses. The 
Midspan questionnaire lacked information on family history of PC, prostate specific antigen 
screening and use of statins. We used plasma total cholesterol level because other measures 
of cholesterol, such as lipoprotein fractions (high and low density lipoproteins), were not 
available. Prostate specific antigen and disease stage data were not available which could be 
used to stratify the analyses based on localised and metastatic prostate cancer. The mean age 
at prostate cancer diagnosis is high and a large proportion of men are likely to die before 
diagnosis. The risk estimates we present might therefore have been affected by differential 
competing mortality risks. However, Cancer Registry data include Death Certificate Only 
diagnoses—and may have included, prostate cancers detected at post-mortem—that will 
attenuate such survival biases. The proportion of men who develop PC is higher among those 
who do not smoke, have a desirable BMI and are taller. The higher proportion of PC among 
these men results from those factors which confer a survival advantage. They live longer and 
therefore experience a longer risk time. However, the observation that height is associated 
with PC does raise the question whether some of those characteristics which promote 
longevity, are also associated with an increased risk of PC or whether such associations 
spuriously result from the influence of competing risk. Height is linked with development of 
many adult cancers [37-39], a meta-analysis of 58 studies also suggested that height is 
positively associated with incident prostate cancer with stronger effect for advance stage and 
aggressive disease [40]. There is some suggestion that height might be confounded by the 
socioeconomic status of the individual, however in our study height was associated with 
overall risk of prostate cancer independent of socioeconomic status. 
Cholesterol, height and obesity are related to mortality from cardiovascular disease [27,41-
43] and early death from cardiovascular disease may be an important consideration. One 
possible scenario is that early cardiovascular disease mortality exhausts the pool of those men 
who would otherwise be susceptible to PC in later life, consequently systematic selection of 
more resilient individual may take place (men with low risk of PC but with high levels of 
traditional cardiovascular risk factors). This potentially could explain the positive association 
between height and overall incident PC, but would fail to explain the association between 
cholesterol and aggressive PC, which we report. A further consideration is detection bias and 
whether some groups are more likely to report their symptoms or have frequent medical 
examinations. 
Further research is needed on cancer registry data to determine whether high-grade prostate 
cancer has differentially increased following increases in metabolic factors associated with 
hypercholesterolaemia. Longer-term follow-up of clinical trials of statins is also required, 
with exclusions of early tumours to minimise the potential effects of “reverse causality” on 
any association. 
Conclusion 
In this population-based cohort study, high cholesterol level was associated with increased 
risk of aggressive prostate cancer; these findings support the results from earlier studies. 
Further research is needed to describe temporal trends in grade-specific prostate cancer and to 
understand the biological mechanisms by which cholesterol and prostate cancer are 
associated. 
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